Previous 10 | Next 10 |
Genmab A/S (NASDAQ: GMAB ) announces positive results from an open-label Phase 3 clinical trial, APOLLO , evaluating a subcutaneous formulation of licensor Janssen Biotech's [a unit of Johnson & Johnson (NYSE: JNJ ) ] Darzalex (daratumumab), combined with pomalidomide and dexametha...
Thesis Summary AbbVie Inc. ( ABBV ) seems, on the surface, like an incredibly undervalued stock offering a 4.75% dividend yield with a payout ratio of under 50%. Upon further inspection though, it becomes clear that due to is dependence on HUMIRA, its best days may be behind it. Still, consi...
The FDA has placed a partial clinical hold on a pivotal Phase 2 clinical trial evaluating ADC Therapeutics' (NYSE: ADCT ) antibody-drug conjugate camidanlumab tesirine in patients with relapsed/refractory Hodgkin lymphoma. More news on: ADC Therapeutics SA, Genmab A/S, Healthcare stock...
Over the past several months, the coronavirus stock market has proven nerve-wracking for even the most seasoned of investors. We are living in unprecedented times. But the basic rules of investing haven't changed, and there are still worthwhile investment opportunities to be found. Eli Lilly...
Seattle Genetics (NASDAQ: SGEN ) and collaboration partner Genmab A/S (NASDAQ: GMAB ) announce positive topline results from a Phase 2 clinical trial, innovaTV 204 , evaluating antibody-drug conjugate (ADC) tisotumab vedotin in patients with relapsed/refractory metastatic cervical cancer....
They say that good things come in threes. And that just might be true for AbbVie (NYSE: ABBV) . The big drugmaker started off the week by receiving good news on Monday. It then announced two positive developments on Wednesday, just in time for the company's top executives to participate in a...
By Máire Lane, PhD, CFA, Senior Research Analyst; Frank Jennings, PhD, Senior Portfolio Manager We look for breakthroughs in healthcare by examining what medical treatment could look like a decade more into the future. When we look for interesting investment ideas, we spend...
The pace of development for a handful of next-generation cancer therapies is about to get a huge boost. AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) signed a collaboration deal on Wednesday involving three clinical-stage cancer drug candidates, plus up to four additional candidates down...
AbbVie (NYSE: ABBV ) and Genmab A/S (NASDAQ: GMAB ) have signed a broad collaboration agreement to jointly develop and commercialize three of Genmab's bispecific antibodies and enter into a discovery research collaboration for future antibody therapeutics for cancer. More news on: AbbVie...
NORTH CHICAGO, Illinois and COPENHAGEN, Denmark , June 10, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced today that AbbVie and Genmab have signed a broad collaboration agreement to jointly develop and commercialize three of Genmab's early-stage in...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 01:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...